TD Cowen Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $59
Ionis Pharmaceuticals (IONS) Receives a Buy From TD Cowen
Ionis Pharmaceuticals Reports WAINZUA Recommended for Approval in the EU by CHMP
Ionis And AstraZeneca's WAINZUA Recommended For EU Approval As First Self-Administered Treatment For HATTR-PN
Express News | Wainzua (Eplontersen) Recommended for Approval in the EU by Chmp for the Treatment of Adults With Polyneuropathy Associated With Hereditary Transthyretin-Mediated Amyloidosis
Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $55